At the news
? MIXEDIMPACT 7/10 8-K filed Feb 25, 2026 at 13:01 ET
Penumbra reported strong 2025 full-year financial results with revenue of $1.4 billion (up 17.5% YoY) and net income of $177.7 million, driven by growth in both thrombectomy and embolization/access products. However, the company will not provide 2026 guidance due to its pending acquisition by Boston Scientific, which also led to the cancellation of its earnings call.
- Revenue of $1.4037 billion for full-year 2025, up 17.5% YoY
- Net income of $177.7 million for full-year 2025, a significant improvement from $14 million in 2024
- Income from operations increased to $189.2 million from $9.3 million in 2024
- Company will not provide 2026 financial guidance due to pending acquisition by Boston Scientific
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access